Literature DB >> 16410352

Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system.

Luca Santi1, Anatoli Giritch, Chad J Roy, Sylvestre Marillonnet, Victor Klimyuk, Yuri Gleba, Robert Webb, Charles J Arntzen, Hugh S Mason.   

Abstract

Plague is still an endemic disease in different regions of the world. Increasing reports of incidence, the discovery of antibiotic resistance strains, and concern about a potential use of the causative bacteria Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine. The use of F1 and V antigens and the derived protein fusion F1-V has shown great potential as a protective vaccine in animal studies. Plants have been extensively studied for the production of pharmaceutical proteins as an inexpensive and scalable alternative to common expression systems. In the current study the recombinant plague antigens F1, V, and fusion protein F1-V were produced by transient expression in Nicotiana benthamiana by using a deconstructed tobacco mosaic virus-based system that allowed very rapid and extremely high levels of expression. All of the plant-derived purified antigens, administered s.c. to guinea pigs, generated systemic immune responses and provided protection against an aerosol challenge of virulent Y. pestis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410352      PMCID: PMC1326254          DOI: 10.1073/pnas.0510014103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium.

Authors:  Sylvestre Marillonnet; Anatoli Giritch; Mario Gils; Romy Kandzia; Victor Klimyuk; Yuri Gleba
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

2.  Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Authors:  Audrey Glynn; Chad J Roy; Bradford S Powell; Jeffrey J Adamovicz; Lucy C Freytag; John D Clements
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine.

Authors:  J D Marshall; P J Bartelloni; D C Cavanaugh; P J Kadull; K F Meyer
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

5.  Plague immunization. VI. Vaccination with the fraction I antigen of Yersinia pestis.

Authors:  K F Meyer; J A Hightower; F R McCrumb
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine.

Authors:  V Yusibov; D C Hooper; S V Spitsin; N Fleysh; R B Kean; T Mikheeva; D Deka; A Karasev; S Cox; J Randall; H Koprowski
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

8.  Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector.

Authors:  Ligang Wu; Lubin Jiang; Zhiai Zhou; Jihua Fan; Qingqi Zhang; Huihui Zhu; Qi Han; Zhengkai Xu
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

9.  Immunisation against plague by transcutaneous and intradermal application of subunit antigens.

Authors:  J E Eyles; S J Elvin; A Westwood; C S Lebutt; H O Alpar; S Somavarapu; E D Williamson
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

10.  Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant.

Authors:  Birgit Wagner; Karin Hufnagl; Christian Radauer; Stefan Wagner; Karin Baier; Otto Scheiner; Ursula Wiedermann; Heimo Breiteneder
Journal:  J Immunol Methods       Date:  2004-04       Impact factor: 2.303

View more
  36 in total

1.  Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents.

Authors:  Brian C Geyer; Latha Kannan; Pierre-Emmanuel Garnaud; Clarence A Broomfield; C Linn Cadieux; Irene Cherni; Sean M Hodgins; Shane A Kasten; Karli Kelley; Jacquelyn Kilbourne; Zeke P Oliver; Tamara C Otto; Ian Puffenberger; Tony E Reeves; Neil Robbins; Ryan R Woods; Hermona Soreq; David E Lenz; Douglas M Cerasoli; Tsafrir S Mor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Authors:  Jeremy L Goodin; David F Nellis; Bradford S Powell; Vinay V Vyas; Jeffrey T Enama; Lena C Wang; Patrick K Clark; Steven L Giardina; Jeffery J Adamovicz; Dennis F Michiel
Journal:  Protein Expr Purif       Date:  2006-12-31       Impact factor: 1.650

Review 3.  Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse.

Authors:  Eric Peterson; S Michael Owens; Ralph L Henry
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  Plant derived veterinary vaccines.

Authors:  L Santi
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

5.  High-level expression of Camelid nanobodies in Nicotiana benthamiana.

Authors:  Yi-Hui Audrey Teh; Tony A Kavanagh
Journal:  Transgenic Res       Date:  2009-10-28       Impact factor: 2.788

Review 6.  Design of virus-based nanomaterials for medicine, biotechnology, and energy.

Authors:  Amy M Wen; Nicole F Steinmetz
Journal:  Chem Soc Rev       Date:  2016-07-25       Impact factor: 54.564

Review 7.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

8.  Expression and immunogenicity of the mycobacterial Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy.

Authors:  Doreen Manuela Floss; Michael Mockey; Galliano Zanello; Damien Brosson; Marie Diogon; Roger Frutos; Timothée Bruel; Valérie Rodrigues; Edwin Garzon; Claire Chevaleyre; Mustapha Berri; Henri Salmon; Udo Conrad; Laurence Dedieu
Journal:  J Biomed Biotechnol       Date:  2010-04-13

9.  Plants as a source of butyrylcholinesterase variants designed for enhanced cocaine hydrolase activity.

Authors:  Katherine E Larrimore; Matthew Barcus; Latha Kannan; Yang Gao; Chang-Guo Zhan; Stephen Brimijoin; Tsafrir Mor
Journal:  Chem Biol Interact       Date:  2012-09-20       Impact factor: 5.192

Review 10.  Plant-made vaccine antigens and biopharmaceuticals.

Authors:  Henry Daniell; Nameirakpam D Singh; Hugh Mason; Stephen J Streatfield
Journal:  Trends Plant Sci       Date:  2009-10-14       Impact factor: 18.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.